The wise choice in mastitis prevention
The wise choice in mastitis prevention
Search
EQVALAN® GOLD
EQVALAN® GOLD
Online application
Online application | FAQ
Internal application
Internal applications | FAQ
Early Careers
Early Careers
Data Careers
Data Careers
Our Global Support Program
Our global support programme
Alexander Guntur
Alexander Guntur, Information Protection and Security officer in Singapore, describes his 14 years with the company as fulfilling.
2021-Your-Guide-to-Partnering-with-Us
Public-Health-Cost-from-AF
Parasiticides
Science and Innovation - Animal Health Innovation - Parasiticides
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Global mobility
We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
Financial health
We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
Western Canada
Boehringer Ingelheim Canada works hand in hand with prominent institutions in Western Canada. Find out more about our partnerships and their initiatives.
Quebec
Boehringer Ingelheim Canada joins forces with top institutions in Quebec to foster excellence in healthcare. Find out more about our partnering activities.
Boehringer Ingelheim - Value Through Innovation
Boehringer Ingelheim - Value Through Innovation
Accessible Customer Service Policy
Accessible Customer Service Policy
Explore our company
Make your next career step at Boehringer Ingelheim. Explore our various fields to find out more about employment opportunities in your area of interest.
about-us-global-card
Even nature isn’t perfect
Even nature isn’t perfect
Udder health during the dry period
Udder health during the dry period
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2
Application Platform Data privacy statement
(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities